Objective: The aim of this study was to evaluate the role of the C677T-MTHFR (methylenetetrahydrofolate reductase)-polymorphism (CC, CT and TT) for vascular complications in liver transplant recipients. Design: Retrospective study. Setting: Hepatology-Transplantation-Unit, Johann Wolfgang Goethe-University, Frankfurt am Main. Subjects: 48 liver transplant recipients were included, no dropouts. Methods: MTHFR polymorphism was detected by PCR amplification and digestion with Hinfl restriction enzyme. Vascular complications after liver transplantation were detected from the patients' records. The total serum homocysteine (HCY) was analyzed with high-pressure liquid chromatography. Results: In the wild-type group (CC), the HCY levels were slightly high (14.071 mM). Among the patients with the CT polymorphism, the HCY values were elevated (22.573 mM). In the homozygous TT group, there was a significant increase (31.276 mM, Po0.01) of the HCY values. The percentage of vascular complications was higher in the heterozygous CT (47%) and homozygous TT (62.5%) group compared with wild-type CC (21%). Patients with a homozygous TT genotype of the MTHFR polymorphism with a vascular complication had a highly significant elevated HCY level compared to the other genotype groups, both with and without any vascular complications (Po0.001). Recipients with an elevated HCY and the TT polymorphism have a higher probability of developing a vascular complication after transplantation (odds ratio: 4.3 and 11.0; 95% confidence interval: 1.15, 12.25 and 1.41, 85.24). Conclusions: The C677T polymorphism in the MTHFR gene and subsequent elevation of the total serum HCY is significantly associated with an increased incidence of vascular complications in liver transplant recipients. Sponsorship: None.
Introduction
A common functional polymorphism, C677T, in the gene encoding methylenetetrahydrofolate reductase (MTHFR), an enzyme involved in homocysteine (HCY) metabolism, has been associated with differences in HCY concentration. MTHFR distribution in the general population is 38-45% for wild type (CC), 45-46% for the heterozygote type (CT) and 10-14% for the homozygote type (TT), (Klerk et al., 2002; Wald et al., 2002; Russo et al., 2003) The C677T polymorphism results in a reduced specific MTHFR activity and thermolability, which leads to higher total homocysteine (tHCY) concentrations. The activity in the heterozygous CT polymorphism is 71%, and 34% in the homozygous TT polymorphism relative to the CC wild-type. MTHFR catalyzes the formation of 5-methyl-tetrahydrofolate (5-methyl-THF) out of 5,10-methylene-THF; 5-methyl-THF is the predominant circulating form of folate, and is a methyl donor for the remethylation of HCY to methionine and DNA methylation (Frosst et al., 1995; van der Put et al., 1996) . Moreover, polymorphism for this variant MTHFR (CT and TT) allele is associated with elevated fasting and postmethionine loading HCY (Kang et al., 1991; Harmon et al., 1996) .
Hyperhomocysteinemia is frequently associated with folate deficiency. Elevated serum HCY concentrations are related to cardiovascular diseases as well as to cerebrovascular diseases such as vascular dementia and mental cognitive dysfunction (Miller et al., 1994; Fassbender et al., 1999; Schachinger et al., 1999; Duthie et al., 2002) . A high HCY level has recently been implicated as a risk factor for cancer and might be considered as a new tumor marker (Wu and Wu, 2002 ) and a pro-proliferative metabolite in vitro (Akoglu et al., 2004) .
Renal function seems to play a key role in HCY clearance. Impaired renal function also leads to elevated HCY levels (Friedman et al., 2002) . Furthermore, beside renal function, obesity and different immunosuppressant protocols are also determinant for elevated total serum HCY in liver transplant recipients. (Akoglu et al., 2006) .
Liver transplant recipients have an increased risk of cardiovascular disease (CVD). Hypertension, hypercholesterolemia, and weight gain are a frequent phenomenon after transplantation. Cardiovascular risk factors and their major contribution to accelerated CVD is an important issue in the long-term management of liver transplant recipients. (Johnston et al., 2002 , Neal et al., 2004 .
The atherogenic mechanism of HCY is not yet well defined, but it might be considered that HCY induces oxidative stress and consequently leads to injury to the vascular wall and other tissues (Stanger et al., 2001) . In the present study, we have investigated the possibility that the MTHFR polymorphism may be a determinant factor for vascular complications. According to these polymorphisms, HCY levels and the incidence of vascular complications in liver transplant recipients were assessed.
Materials and methods

Patients
All participants gave their written informed consent before entering the study, and the protocol was approved by the local ethics committee. Forty-eight stable liver transplant recipients patients, 34 male subjects (age, 50711 years) and 14 female subjects (age, 52713 years), seen regularly at our outpatient clinic were included into this study (Table 1) . These patients, on average 874 years after transplantation, were tested for serum HCY and the MTHFR C667T polymorphism. Vascular complications after liver transplantations such as chronic heart disease (CHD), stroke, periphere vascular disease (PVD), ischemic type biliary lesion (ITBL) and sinus vein thrombosis (SVT) were detected from the patients files.
Clinical chemistry
Blood samples were obtained after overnight fasting and immediately (within 1 h) analyzed for total serum HCY according to the manufacturer's instructions (Immundiagnostik, Bensheim, Germany). In brief, samples were centrifuged at 4000 r.p.m. for 10 min. After protein denaturation, 20 ml of the probe was injected into a high-performance liquid chromatograph (Merck-Hitachi, Darmstadt, Germany) (Minniti et al., 1998) .
Isolation of DNA and genotype analysis Genomic DNA was isolated from 300 ml blood sample (Amersham Pharmacia biotech DNA isolation kit, NJ, USA) MTHFR C677T polymorphisms were detected by PCR amplification and digestion with HinfI restriction enzyme of a 198-bp DNA fragment in exon 4 of the MTHFR gene. In brief, the amplified fragment was cleaved with HinfI, which recognizes the C-T substitution. This nucleotide substitution corresponds to the conversion of the Ala residue to Val in the MTHFR encoding protein. The 198-bp fragment containing the Ala allele is not digested by HinfI, whereas the fragment containing the Val allele of the MTHFR C677 is digested by HinfI into 175-and 23-bp fragments. The HinfI-digested PCR fragments were electrophoresed in 3.0% agarose gels and stained with ethidium bromide (Frosst et al., 1995) .
Statistical analysis
Results are expressed as mean7s.e.m. Differences in continuous variables between two or more groups were analyzed using unpaired t-tests and analysis of variance (ANOVA). To examine the significance of the association between variables, the Fisher's exact test with a two-sided P value was performed and the odds ratio was calculated. Statistical analysis was performed on an Apple Macintosh OsX with InStat 3 Software (GraphPad, San Diego, CA, USA).
Results
Demographic characteristics are listed in Table 1 . The average age of the patients was 51712 years. The duration Table 2 .
For mainstay immunosuppression, 36 patients received tacrolimus, 14 cyclosporine, three mycofenolate, four rapamycin and some in combinations (Table 3 ). The lowest levels of serum HCY were detected in recipients with tacrolimus mainstay immunosuppression. The HCY levels in patients receiving cyclosopin A and rapamycin were significantly elevated compared to the tacrolimus group (Po0.01, Po0.05, ANOVA).
The C677T polymorphism in the MTHFR gene was found in its homozygous (TT) form in 19% and its heterozygous form in 48% (CT); 33% were homozygous for the wild type (CC).
The corresponding HCY levels among the different MTHFR polymorphisms are shown in Figure 1 . In the wild-type group (CC) the HCY levels were slightly high (14.071 mM). The HCY values were more elevated (22.573 mM) among the patients with the CT polymorphism,. In the homozygous TT group, there was a significant increase (31.276 mM, Po0.01, ANOVA) of the HCY values.
The percentage of vascular complications in the different MTHFR genotype groups was higher in the heterozygous CT (47%) and homozygous TT (62.5%) groups. (Figure 1) .
If we compare the HCY levels between recipients depending on vascular complications, without considering the MTHFR genotype groups, HCY levels were almost significantly increased in the vascular complications group (Figure 2 , 23.773mM vs 16.871 mM, P ¼ 0.05, t-test).
Subgroup analysis among the specific type of vascular complications (CHD, stroke, PVD, ITBL and SVT) did not show any significant differences in HCY levels compared to the group without any vascular complications (Figure 3 , ns, ANOVA). Therefore we performed another MTHFR genotypebased subgroup analysis. Patients with a homozygous TT genotype of the MTHFR polymorphism with a vascular complication had a highly significant rise in HCY level compared to the other genotype groups, both with and without any vascular complications (Figure 4 , Po0.001, Po0.01, ANOVA).
A HCY level above 15 mM was determinant for a 4.3-fold higher probability of having a vascular complication after OLT; a homozygous genotype of the MTHFR showed a 11.0-fold higher probability (Table 4) . 
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Discussion
Elevated HCY levels are common in all patients studied after liver transplantation. In our patients, there was an obvious coherence between the genotype of the MTHFR polymorphism, HCY levels and the incidence of vascular complications after liver transplantations. HCY, a sulphur-containing amino acid, is a reliable marker for impaired folate metabolism. In addition, elevated HCY concentrations are a well-described risk factor for vascular diseases and are an additional important predictor of mortality in patients with CHD (Ueland et al., 2000) . Sudan et al. described the causes of late death in liver transplant recipients, five or more years after transplantation. The mortality due to cardiovascular events was 19% (Sudan et al., 1999) . Other publications have given the mortality from CVD as between 1.5 and 3% of the total number of patients alive after one year. In heart transplant recipients, the main causes for late secondary organ loss are vascular diseases and their complications (Abbasoglu et al., 1997; Pruthi et al., 2001; Rabkin et al., 2001; Eisen et al., 2003) . Classical cardiovascular risk factors such as hypertension, obesity, diabetes mellitus etc., were held responsible for these data.
The allelic frequency of the MTHFR polymorphism in our liver transplant recipients is not comparable with healthy individuals. Several studies for the allelic frequencies for MTHFR polymorphism gave 38-45% for the wild type (CC), 45-46% for the heterozygous type (CT) and 10-15% for the homozygous type (TT) (1,2,3). Due to our sample size this observation still needs to be discussed critically. However, our study shows that homozygosity for the C677T transition in the MTHFR gene in liver transplant recipients results in a further increase in total HCY levels and vascular complications.
The enzyme methylenetetrahydrofolate-homocysteinemethyltransferase remethylates HCY to methionine. This metabolic pathway requires the enzyme MTHFR for conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (5-MTHF), the active form of folate. The reaction provides the methyl group for methionine synthesis from HCY by methyl-cobalamin. A decreased MTHFR activity caused by polymorphism of the MTHFR alleles (CT and TT) may result in increased total HCY because of a further impairment of methylation processes caused by low 5-MTHF levels (Fodinger et al., 1999) . Unfortunately, the measurement of 5-MTHF was not possible in our laboratory to confirm this findings in our patients.
ITBLs lead to considerable morbidity after orthotopic liver transplantation. The exact pathogenesis is unknown. The poorer condition of the arterial system in older patients may impair regular perfusion of bile-duct capillaries. The majority of ITBLs might be classified as a kind of IBL (ischemic biliary lesions). In this sense, IBLs can occur as either macroangiopathic (arterial occlusion, stenosis, thrombosis) or microangiopathic biliary lesions (inadequate perfusion of small vessels) (Moench et al., 2003) . Cases of diffuse bile-duct injury with adequate perfusion during organ procurement should continue to be classified as ITBLs. However, the HCY levels (2173 mMol/l) are elevated in our patients with ITBL and the incidence is comparable to other studies (18%) (Moench et al., 2003) . HCY as a risk factor for vascular Evaluation of the role of the C677T-MTHFR B Akoglu et al diseases might therefore also be considered as a risk factor for macroangiopathic or microangiopathic biliary lesions. Liver transplant recipients treated with cyclosporine had higher serum HCY concentrations than tacrolimus-treated patients. Independent of cyclosporine levels and individual dosage, it is not known how cyclosporine interferes with HCY metabolism. Cyclosporine, which has well-elucidated tubular effects (Shihab, 1996) , might therefore interfere with the HCY clearance and/or catabolism at this level. However, the interference in the trans-sulfuration pathway might be another cause of increased HCY levels in these patients. Overall, rapamycin-treated recipients showed the highest levels of serum HCY. In turn, patients with tacrolimus as the mainstay immunosuppressive showed significantly lower levels of serum HCY compared with cyclosporine, mycofenolate, and rapamycin without any significant difference of kidney function (data not shown). Quiroga et al. (2001) showed higher HCY levels in cyclosporine-treated renal transplant recipients than in the tacrolimus group. Conversely, Fernandez et al. (Fernandez-Miranda et al., 2000; Fernandez-Miranda et al., 2001) could not confirm these findings in renal recipients, but could do so in patients with liver transplants.
In our data, there was a significantly increased odds ratio in patients with vascular complications for elevated HCY levels (415 mM) and the homozygous genotype TT of the MTHFR gene. Other classical cardiovascular risk factors had no effect on the probability to develop a vascular complication after liver transplantation. This might be related to the prior selection of transplantation candidates in the pretransplant evaluation time. However, due to the sample size, we were unable to perform multivariate analysis in our study cohort to determine independent variables. Elevated HCY levels after liver transplantation are frequent phenomena obviously resulting from different causes. However, genetic polymorphism of the MTHFR gene seems to be the most reliable cause for increased HCY concentrations after liver transplantation. Therefore, genetic screening for MTHFR polymorphism and subsequent additional treatment with substances such as folic acid might be beneficial in lowering serum HCY levels (Bosy-Westphal et al., 2003) and reducing morbidity from vascular diseases or other complications of hyperhomocysteinemia. The authors want to emphasize that the importance of HCY in developing vascular complications remains unclear. Further long-term studies are needed to discover whether patients with elevated HCY levels have different rates of survival compared with recipients with lower levels. Furthermore, it is not known whether treatments with substances such as folic acid are able to change the morbidity and mortality after liver transplantation by lowering the total serum HCY.
